Donald Stanski

780 total citations
15 papers, 510 citations indexed

About

Donald Stanski is a scholar working on Statistics and Probability, Economics and Econometrics and Surgery. According to data from OpenAlex, Donald Stanski has authored 15 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Statistics and Probability, 5 papers in Economics and Econometrics and 2 papers in Surgery. Recurrent topics in Donald Stanski's work include Statistical Methods in Clinical Trials (6 papers), Pharmaceutical Economics and Policy (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Donald Stanski is often cited by papers focused on Statistical Methods in Clinical Trials (6 papers), Pharmaceutical Economics and Policy (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Donald Stanski collaborates with scholars based in United States, United Kingdom and Sweden. Donald Stanski's co-authors include Russell Wada, Sven Björkman, Yung J. Sohn, Lewis B. Sheiner, Wayne A. Colburn, Jürgen Venitz, Lawrence J. Lesko, Philip Chaikin, Ronald D. Miller and Peter P. Lee and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Reviews Drug Discovery.

In The Last Decade

Donald Stanski

15 papers receiving 484 citations

Peers

Donald Stanski

APM

SURGE

PHARM

Elodie L. Plan Sweden

John Devane Ireland

Eliane Fuseau France

Peter Lockwood United States

Sunny Chapel United States

Natalie Dayneka Canada

C. Dubruc France

M. René Bouw United Kingdom

Maria Sunzel Sweden

Jonathan Palmer United Kingdom

Elodie L. Plan Sweden

Donald Stanski

85 ×0.9

38 ×0.5

APM

56 ×0.8

SURGE

164 ×2.4

51 ×0.9

PHARM

Citations per year, relative to Donald Stanski Donald Stanski (= 1×) peers Elodie L. Plan

Countries citing papers authored by Donald Stanski

Since Specialization

Citations

This map shows the geographic impact of Donald Stanski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Stanski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Stanski more than expected).

Fields of papers citing papers by Donald Stanski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Stanski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Stanski. The network helps show where Donald Stanski may publish in the future.

Co-authorship network of co-authors of Donald Stanski

This figure shows the co-authorship network connecting the top 25 collaborators of Donald Stanski. A scholar is included among the top collaborators of Donald Stanski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald Stanski. Donald Stanski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Mitchell, Pat, Bengt Hamrén, Gabriel Helmlinger, et al.. (2018). Integrating dose estimation into a decision‐making framework for model‐based drug development. Pharmaceutical Statistics. 17(2). 155–168. 1 indexed citations

Helmlinger, Gabriel, Nidal Al‐Huniti, Sergey Aksenov, et al.. (2017). Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet. European Journal of Pharmaceutical Sciences. 109. S39–S46. 24 indexed citations

Al‐Huniti, Nidal, Diansong Zhou, Hongmei Xu, et al.. (2017). Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label. Clinical Pharmacology & Therapeutics. 102(5). 741–744. 8 indexed citations

Al‐Huniti, Nidal, Eric Masson, Gabriel Helmlinger, et al.. (2017). Dynamic predictions of patient survival using longitudinal tumor size in non-small cell lung cancer: Approach towards personalized medicine.. Journal of Clinical Oncology. 35(15_suppl). e20606–e20606. 1 indexed citations

Röshammar, Daniel, Joakim Nyberg, Tomas Andersson, et al.. (2016). Exposure‐Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. The Journal of Clinical Pharmacology. 57(5). 573–583. 3 indexed citations

Dumortier, Thomas, Michael Looby, Olivier Luttringer, et al.. (2015). Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: A model‐based approach. Clinical Pharmacology & Therapeutics. 97(4). 411–418. 4 indexed citations

Orloff, John J. & Donald Stanski. (2011). Innovative approaches to clinical development and trial design. SHILAP Revista de lepidopterología. 8 indexed citations

Kern, Steven E., et al.. (2010). Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs. Journal of Pharmacokinetics and Pharmacodynamics. 37(6). 629–644. 43 indexed citations

Orloff, John J., Frank L. Douglas, José Cirı́aco Pinheiro, et al.. (2009). The future of drug development: advancing clinical trial design. Nature Reviews Drug Discovery. 8(12). 949–957. 110 indexed citations

10.

Rolan, Paul, Meindert Danhof, Donald Stanski, & Carl C. Peck. (2006). Current issues relating to drug safety especially with regard to the use of biomarkers: A meeting report and progress update. European Journal of Pharmaceutical Sciences. 30(2). 107–112. 7 indexed citations

11.

Drover, David R., et al.. (2000). Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clinical Therapeutics. 22(12). 1443–1461. 58 indexed citations

12.

Lesko, Lawrence J., Philip Chaikin, Wayne A. Colburn, et al.. (2000). Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development. The Journal of Clinical Pharmacology. 40(12). 1399–1418. 123 indexed citations

13.

Drover, David R., et al.. (1999). The comparative pharmacokinetics of zaleplon and zolpidem. Clinical Pharmacology & Therapeutics. 65(2). 168–168. 4 indexed citations

14.

Björkman, Sven, Russell Wada, & Donald Stanski. (1998). Application of Physiologic Models to Predict the Influence of Changes in Body Composition and Blood Flows on the Pharmacokinetics of Fentanyl and Alfentanil in Patients . Anesthesiology. 88(3). 657–667. 55 indexed citations

15.

Cronnelly, Roy, Donald Stanski, Ronald D. Miller, Lewis B. Sheiner, & Yung J. Sohn. (1979). Renal Function and the Pharmacokinetics of Neostigmine in Anesthetized Man. Anesthesiology. 51(3). 222–226. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact